Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -34.36% is 32% below its 5-year average of -26.10%, around the middle of its 5-year range (-73.92%–25.11%).
160.00% below its 12-month average of -13.22%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 14.32%.
EBITDA MARGIN
-34.36%
EBITDA MARGIN AVG TTM
-13.22%
EBITDA MARGIN AVG 3Y
-13.02%
EBITDA MARGIN AVG 5Y
-26.10%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-160.00%
CURRENT VS 3Y AVG
-163.83%
CURRENT VS 5Y AVG
-31.62%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$83.22M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$84.50M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$82.37M
EBITDA Margin
-4911.29%
TTM Avg
-4911.29%
3Y Avg
-4895.51%
5Y Avg
-4835.22%
Market Cap
$81.74M
EBITDA Margin
-3237.56%
TTM Avg
-3237.56%
3Y Avg
-2112.78%
5Y Avg
-1492.65%
Market Cap
$84.04M
EBITDA Margin
-63075.78%
TTM Avg
-211942.49%
3Y Avg
-892870.62%
5Y Avg
-626625.43%
Market Cap
$82.08M
EBITDA Margin
-8103.88%
TTM Avg
-7583.93%
3Y Avg
-8667.05%
5Y Avg
-7944.60%
Market Cap
$80.47M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| LENSAR Inc (LNSR) | $82.66M | -34.36% | -13.22% | -13.02% | -26.10% |
| Telomir Pharmaceuticals, Inc. Common Stock (TELO)vs › | $83.22M | N/A | N/A | N/A | N/A |
| Cognition Therapeutics, Inc. (CGTX)vs › | $84.50M | N/A | N/A | N/A | N/A |
| Humacyte, Inc. (HUMA)vs › | $82.37M | -4911.29% | -4911.29% | -4895.51% | -4835.22% |
| MediciNova, Inc. (MNOV)vs › | $81.74M | -3237.56% | -3237.56% | -2112.78% | -1492.65% |
| ProMIS Neurosciences, Inc. (PMN)vs › | $84.04M | -63075.78% | -211942.49% | -892870.62% | -626625.43% |
| Cardiff Oncology, Inc. (CRDF)vs › | $82.08M | -8103.88% | -7583.93% | -8667.05% | -7944.60% |
| Citius Oncology, Inc. (CTOR)vs › | $80.84M | N/A | N/A | N/A | N/A |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $80.47M | N/A | N/A | N/A | N/A |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $86.09M | 31.45% | -14.67% | -906.21% | -1050.55% |
Gross Margin
48.0%
EBITDA Margin
-34.4%
Operating Margin
-42.1%
Net Margin
57.6%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 14.32% |
| 2026-03-31 | 25.11% |
| 2025-12-31 | -23.37% |
| 2025-09-30 | -44.87% |
| 2025-06-30 | -37.27% |
| 2025-03-31 | -33.29% |
| 2024-12-31 | -1.10% |
| 2024-09-30 | -0.05% |
| 2024-06-30 | -5.17% |
| 2024-03-31 | -18.22% |
| 2023-12-31 | -16.83% |
| 2023-09-30 | -11.82% |
| 2023-06-30 | -16.75% |
| 2023-03-31 | -42.50% |
| 2022-12-31 | -17.20% |
| 2022-09-30 | -41.77% |
| 2022-06-30 | -73.92% |
| 2022-03-31 | -62.45% |
| 2021-12-31 | -28.00% |
| 2021-09-30 | -66.04% |
| 2021-06-30 | -47.01% |
| 2021-03-31 | -64.73% |
| 2020-12-31 | -75.59% |
| 2020-09-30 | -61.57% |
| 2020-06-30 | -63.36% |
| 2020-03-31 | -39.03% |
| 2019-12-31 | -12.60% |
| 2019-09-30 | -62.22% |
| 2019-06-30 | -23.99% |
| 2019-03-31 | -23.99% |
